Currently, it is believed that TLR preconditioning can alter TLR signaling pathways after ischemia, mainly manifested as the activation of the TLR4/TRIF signaling pathway and the inhibition of the TLR4/MyD88 signaling pathway, thereby increasing the production of anti-inflammatory cytokines, reducing the generation of pro-inflammatory cytokines [81], and reducing the inflammatory damage of cerebral ischemia. This evidence concerns the gene MYD88 and brain ischemia.